Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
0.0%
operating margin TTM
0.0%
revenue TTM
2.99 Million
revenue per share TTM
0.04$
valuation ratios | |
|---|---|
| pe ratio | -3.70 |
| peg ratio | -0.08 |
| price to book ratio | 2.42 |
| price to sales ratio | 0.00 |
| enterprise value multiple | -3.48 |
| price fair value | 2.42 |
profitability ratios | |
|---|---|
| gross profit margin | 0.0% |
| operating profit margin | 0.0% |
| pretax profit margin | 0.0% |
| net profit margin | 0.0% |
| return on assets | -59.87% |
| return on equity | -57.15% |
| return on capital employed | -70.81% |
liquidity ratios | |
|---|---|
| current ratio | 11.73 |
| quick ratio | 11.73 |
| cash ratio | 5.72 |
efficiency ratios | |
|---|---|
| days of inventory outstanding | 0.00 |
| operating cycle | 0.00 |
| days of payables outstanding | 3,377.16 |
| cash conversion cycle | -3,377.16 |
| receivables turnover | 0.00 |
| payables turnover | 0.11 |
| inventory turnover | 0.00 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.00 |
| debt equity ratio | 0.00 |
| long term debt to capitalization | 0.00 |
| total debt to capitalization | 0.00 |
| interest coverage | 0.00 |
| cash flow to debt ratio | 0.00 |
cash flow ratios | |
|---|---|
| free cash flow per share | -0.28 |
| cash per share | 0.86 |
| operating cash flow per share | -0.28 |
| free cash flow operating cash flow ratio | 1.00 |
| cash flow coverage ratios | 0.00 |
| short term coverage ratios | 0.00 |
| capital expenditure coverage ratio | 0.00 |
Frequently Asked Questions
When was the last time Inhibikase Therapeutics, Inc. (NASDAQ:IKT) reported earnings?
Inhibikase Therapeutics, Inc. (IKT) published its most recent earnings results on 14-11-2025.
What is Inhibikase Therapeutics, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Inhibikase Therapeutics, Inc. (NASDAQ:IKT)'s trailing twelve months ROE is -57.15%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Inhibikase Therapeutics, Inc. (IKT) currently has a ROA of -59.87%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did IKT's net profit margin stand at?
IKT reported a profit margin of 0.0% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is IKT's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 11.73 in the most recent quarter. The quick ratio stood at 11.73, with a Debt/Eq ratio of 0.00.